No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users.
The relationship between CCR5 and CCR2b genotypes and human immunodeficiency virus (HIV)-1 disease progression was studied among the 108 seroconverters of the Amsterdam cohort of injecting drug users (IDUs). In contrast to earlier studies among homosexual men, no effect on disease progression of the CCR5 Delta32/+ and the CCR2b 64I/+ genotypes was found, when progression to AIDS, death, or a CD4 cell count <200/microL was compared by a Cox proportional hazards model. Furthermore, CD4 cell decline (by a regression model for repeated measurements) and virus load in the first 3 years after seroconversion did not differ between the CCR5 and CCR2b wild type and heterozygous genotypes. A nested matched case-control study also revealed no significant effect of the CCR5 and CCR2b mutations. Immunologic differences between IDUs and homosexual men may account for the observed lack of effect. Alternatively, difference in transmission route or characteristics of the HIV-1 variants that circulate in IDUs could also explain this phenomenon.